Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. (October 2022)

Record Type:
Journal Article
Title:
Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. (October 2022)
Main Title:
Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial
Authors:
Hong, D.
Shergill, A.
Bazhenova, L.
Cho, B.C.
Heist, R.
Moreno, V.
Falchook, G.S.
Nagasaka, M.
Cassier, P.
Besse, B.
Kim, D.W.
Yoon, S.
Le, X.
Zhao, T.
Atwal, S.
Park, E.
Lee, J.
Abstract:
Is Part Of:
European journal of cancer. Volume 174(2022)Supplement 1
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Issue Display:
Volume 174, Issue 1 (2022)
Year:
2022
Volume:
174
Issue:
1
Issue Sort Value:
2022-0174-0001-0000
Page Start:
S72
Page End:
Publication Date:
2022-10
Subjects:
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994
Journal URLs:
http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/S0959-8049(22)00992-3 ↗
Languages:
English
ISSNs:
0959-8049
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:
24178.xml